JIDEYTRO frequently asked questions

JIDEYTRO is part of a category of ROS1-targeted treatments called tyrosine kinase inhibitors, or TKIs. TKIs, like JIDEYTRO, interrupt the messages that cancer cells send. This may make tumors shrink or disappear. If the cancer disappears, that does not mean it has been cured.

JIDEYTRO is an oral medication with once-daily dosing that can be taken with or without food. You should take JIDEYTRO exactly as your healthcare provider tells you to take it. Learn more about dosing and considerations for taking JIDEYTRO.

The most common side effects of JIDEYTRO include swelling, numbness or tingling in your arms or legs, constipation, tiredness, and shortness of breath. These are not all the possible side effects of JIDEYTRO. Call your doctor for medical advice about side effects. See more information about the safety of JIDEYTRO.

If you enroll in the Copay Assistance Program, you could pay as little as $0 for JIDEYTRO if you have commercial insurance and meet eligibility requirements. If you do not have insurance, your insurance does not cover JIDEYTRO, or you are concerned about the cost of your medication, the Patient Assistance Program may be able to provide your medication at no cost if you meet eligibility requirements. Learn more about financial assistance.

If you or a loved one have been affected by ROS1+ NSCLC, you are not alone. There are several advocacy and support groups for patients, caregivers, and families that may be able to help.

ROS1+ NSCLC is a type of NSCLC in which the cancer cells have an abnormal change, often called a "fusion," in a gene called ROS1. Identifying an abnormal ROS1 gene may make you a candidate for targeted therapies. Learn more about ROS1+ NSCLC.

Cancer biomarkers are proteins and genes found in cancer cells that can be tested to provide important details about a person’s cancer.

In people living with NSCLC, genes like ROS1 may have undergone an abnormal change, often called a "fusion." When this type of biomarker is found, doctors can prescribe medicine that targets the cancer. Learn more about ROS1+ NSCLC.